Integrating pharmacogenetic and clinical factors to predict the C0/D/W-based tacrolimus phenotype in kidney transplantation

Single-center retrospective study, 77 adult kidney transplant recipients, analysis of pharmacogenetic (CYP3A5*1, CYP3A4*22) and clinical (age, weight, hematocrit, albumin) factors predictive of tacrolimus C0/D/W (trough concentration/dose/weight) ratio

A single-center retrospective study in 77 adult kidney transplant recipients analyzes pharmacogenetic (CYP3A51, CYP3A422) and clinical factors predictive of tacrolimus C0/D/W ratio — a simple composite parameter reflecting bioavailability and facilitating dose individualization. CYP3A5*1 is the major pharmacogenetic factor explaining interindividual variability, with hematocrit and albumin also contributing. An integrative pharmacogenetic-clinical model is proposed to predict tacrolimus pharmacokinetic phenotype in routine clinical practice.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Tacrolimus dose individualization remains a major clinical challenge in transplantation, with marked interindividual variability. This model integrating CYP3A5/CYP3A4 + clinical factors is more predictive than genotyping alone, and is implementable without complex informatics. A step toward pharmacogenomics-guided prescribing in kidney transplantation.

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 7/10